Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective lifted by Canaccord Genuity Group from $158.00 to $160.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. A number of other research analysts also recently issued reports on NBIX. Evercore ISI dropped their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an …

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose

William H. Rastetter Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) Director William H. Rastetter sold 30,000 shares of the company’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director now directly owns 37,491 shares […]

Guggenheim Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $165.00

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target boosted by investment analysts at Guggenheim from $155.00 to $165.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price suggests a potential upside of 35.76% from the stock’s current price. Several other […]